-
Most Recent
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Big Pharma Eyes Rare-Disease Revenue Stream
Large drug firms are starting to look beyond common maladies to keep the cash coming.
Johnson & Johnson a Safe Play for Income
JNJ's financials are solid, and the company is making strides toward getting 11 new drugs approved by the end of 2015.
Vertex Scores Big With Hepatitis Drug
The company's new hepatitis C medication, Incivek, is outselling Merck's drug by 4-to-1. What's more, it's close to adding another drug to its arsenal.
Insider Bets Big That Seattle Genetics Cancer Drug Can Buck Dendreon Effect
Similar drugs in Adcetris' high price range also faring well, which is cause for optimism, but SGEN's lack of other drugs near the end of the pipeline should make investors wary.
Teva Pharmaceutical: A Good Buy for Value Investors
Teva Pharmaceuticals, a major force in the generic drug realm, delivers on the fundamentals and is a worthy value stock.
Amgen: The Don’t-Bother Biotech
Despite being a cash cow, Amgen is stuck in a middle ground where it isn't growing, nor is it producing a tempting dividend.
No Reason to Hold Merck
As long as this big-name pharmaceutical's growth continues to stagnate, its stock price isn't going anywhere, either.
Big Pharma Cash Hoards Seem Earmarked for Opportunities in Emerging Markets
Pfizer and Merck doing little to put money toward expanding their business, and even Johnson & Johnson held back some cash in a purchase of Synthes.
More Tightly Focused Biogen Appears to Have Greater Upside
With many of its drugs in Phase III clinical trials, including a promising treatment for MS, Biogen has upside potential.
Is it Time to Follow Ichan Out of Amgen — and Other Biotechs?
Investor Carl Ichan recently dumped several biotechs. However, Amgen's sales are strong, and with other positives, it's possible he cut bait too soon.
Big Pharma Banking on New Cancer Treatment Approach to Boost Sales
GlaxoSmithKline, Eli Lilly and Novartis are among the companies studying epigenetics -- a new approach to fighting cancer that is already seeing some success.
Among Biotechs, Cubist Has Held its Own During Recent Downturn
Cubist has had several pieces of good news during the past quarter, including a promotion agreement and a settled patent dispute. However, it still needs more products.
Is it Time to Join CEO and Jump on Celgene Shares?
Bog Hugin, CEO of Celgene, recently bought 10,000 shares of his own company -- and for plenty of good reasons.
Campaign to Kill Medco-Express Scripts Deal Likely Futile
It's not very likely that major pharmaceuticals will be able to prevent Express Scripts from acquiring Medco. But they do have good reason to try.
Pfizer Still Is a Sick Corporate Patient
Pfizer's good second-quarter showing is overshadowed by upcoming losses of patent protection and no guaranteed shot at regenerating revenue.
Sides Form on Medco-Express Scripts Deal
With the Federal Trade Commission likely to give the deal a close eye, analysts and investors sound off varying degrees of optimism and pessimism about this venture.
A Tuesday Thrashing for Dow Jones Stocks
Economic concerns drag Dow slightly lower, with Pfizer, Home Depot, GE and Bank of America all losing early Tuesday.
Allergan’s Good Looks May Be Too Pricey
Expected uptick in breast implants, wrinkle fillers is good news for Botox creator, but many investors think AGN still costs too much.
Medical Research Firms May See a Profit Pinch
Relationships with Big Pharma are changing the game.
